Neo-adjuvant chemotherapy in fertility-sparing cervical cancer treatment
| Autor: | Jacqueline M. Tromp, Constantijne H. Mom, Jacobus van der Velden, Nerissa P. Denswil, Jenneke C Kasius |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty media_common.quotation_subject medicine.medical_treatment Uterine Cervical Neoplasms Fertility Fertility sparing surgery 03 medical and health sciences 0302 clinical medicine Medicine Chemotherapy Humans Uterine Cervical Neoplasms/drug therapy Neo adjuvant chemotherapy Child Adjuvant media_common Neoplasm Staging Cervical cancer 030219 obstetrics & reproductive medicine business.industry Mortality rate Obstetrics and Gynecology Fertility Preservation General Medicine medicine.disease Chemotherapy regimen Neoadjuvant Therapy Surgery Neoplasm Recurrence Treatment Outcome Local Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female Neoplasm Recurrence Local business Cohort study |
| Zdroj: | Kasius, J C, van der Velden, J, Denswil, N P, Tromp, J M & Mom, C H 2021, ' Neo-adjuvant chemotherapy in fertility-sparing cervical cancer treatment ', Baillière's Best Practice and Research. Clinical Obstetrics and Gynaecology, vol. 75, pp. 82-100 . https://doi.org/10.1016/j.bpobgyn.2021.01.010 |
| ISSN: | 1521-6934 |
| Popis: | The current review provides a literature overview of studies assessing the oncological and fertility outcomes of treatment with neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer >2 cm. Six cohort studies were included showing severe heterogeneity regarding patient selection, chemotherapy regimen, and surgical approach. In total, 111 patients were studied, with overall favorable characteristics. Patients were on average 29 years old, had a tumor of 36 mm, no lymph node metastasis, and response to chemotherapy. In approximately 5-year follow-up, the recurrence rate was 13% (0%-21%) and overall death rate 2.7% (0%-10%). Three patients were alive with recurrent disease (2.7% and 0%-11%). Of the 111 patients, 90 underwent successful fertility-sparing treatment (83%). Roughly one-third conceived and one-fourth had a healthy live-born child. More research is essential to determine proper selection criteria for fertility-sparing treatment of cervical cancer >2 cm and the optimal treatment management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect